Enzyme News and Research

RSS

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.

29 Jun 2011

New insights into 'sundowning' syndrome

New research provides the best evidence to date that the late-day anxiety and agitation sometimes seen in older institutionalized adults, especially those with dementia, has a biological basis in the brain.

28 Jun 2011

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Why is antibody diversity important? Think about it like this, said Myron Goodman, who is an author on the paper: "Why don't you die when I sneeze? It's because you have a powerful immune system. And the way to get a decent immune system is for your body to have a way to respond to insults it has never seen before."

28 Jun 2011

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

ACS to honor Brookhaven Lab's senior chemist for brain research

Joanna Fowler, a senior chemist and director of radiotracer chemistry, instrumentation, and biological imaging at the U.S. Department of Energy's Brookhaven National Laboratory, is one of 23 women from around the world who has been chosen to receive a Distinguished Women in Chemistry/Chemical Engineering Award, sponsored by the American Chemical Society (ACS).

27 Jun 2011

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.

24 Jun 2011

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

Two decades after Rutgers scientists began working with Paul Janssen, a legendary drug developer and founder of Johnson & Johnson subsidiary Janssen Pharmaceutica, to create new and potent drugs to fight AIDS, the FDA has approved the second anti-HIV drug that came from this collaboration.

24 Jun 2011

Youngevity announces acquisition of R-Garden

Youngevity Essential Life Sciences, an international nutritional products company, announced its acquisition of R-Garden, Inc. The acquisition of R-Garden's Customers, Distributors, and Product Line expands Youngevity's already substantial "network cloud" of Distributors and Customers and their social networking reach.

24 Jun 2011

Stresses can change gene expression without DNA sequence change

None of us are strangers to stress of various kinds. It turns out the effects of all those stresses can change the fate of future generation, influencing our very DNA without any change to the underlying sequence of As, Gs, Ts and Cs. Now, researchers reporting in the June 24th issue of Cell, a Cell Press publication, have new evidence that helps to explain just how these epigenetic changes really happen.

24 Jun 2011

Research offers avenue for creating Alzheimer's and HIV therapeutics

A new advance by UCLA biochemists has brought scientists one step closer to developing treatments that could delay the onset of Alzheimer's disease and prevent the sexual transmission of HIV.

24 Jun 2011

New VAAST software tool can identify disease-causing mutations in rare genetic disorders

Harnessing the new generation of rapid, highly accurate gene-sequencing techniques, a research team has identified the disease-causing mutation in a newly characterized rare genetic disease, by analyzing DNA from just a few individuals.

24 Jun 2011

Potential new approach for treating myelofibrosis

A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers.

24 Jun 2011

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

23 Jun 2011

Resveratrol may make old age more tolerable, but not prevent it

A University of Florida review of research finds the polyphenol compound known as resveratrol found in red wine, grapes and other fruits may not prevent old age, but it might make it more tolerable.

23 Jun 2011

Monash researchers receive MMV Project of the Year award for new anti-malarial drug candidate

Monash University is collaborating on the development of a potential new drug to cure malaria throughout the world.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

Enzyme News and Research

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

New insights into 'sundowning' syndrome

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

ACS to honor Brookhaven Lab's senior chemist for brain research

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

Youngevity announces acquisition of R-Garden

Stresses can change gene expression without DNA sequence change

Research offers avenue for creating Alzheimer's and HIV therapeutics

New VAAST software tool can identify disease-causing mutations in rare genetic disorders

Potential new approach for treating myelofibrosis

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Resveratrol may make old age more tolerable, but not prevent it

Monash researchers receive MMV Project of the Year award for new anti-malarial drug candidate

Telaprevir drug shows promise in curing hepatitis C infection

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo